BAY 2927088（Sevabertinib）
BAY 2927088（Sevabertinib) is the first non-covalent, potent, oral, selective, and reversible inhibitor of tyrosine kinase that potently inhibits mutant HER2 and mutant EGFR in preclinical models. It targets Exon 20 insertions in non-small-cell lung carcinoma (NSCLC) patients.
| Trivial name | Sevabertinib |
| Catalog Number | E4997 |
| Molecular Formula | C19H26O3 |
| CAS# | 2521285-05-0 |
| Inchi | InChI=1S/C19H26O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,18,20-21H,3-8H2,1-2H3/t12-,13+,15-,18-,19-/m0/s1 |
| Inchi Key | CQOQDQWUFQDJMK-SSTWWWIQSA-N |
| SMILES | CC12CCC3C(C1CCC2O)CCC4=CC(=C(C=C34)OC)O |
| Size | 1g |
| Supplier Page | http://www.selleckchem.com/products/bay-2927088-sevabertinib.html |
| Additional Information | https://file.selleck.cn/downloads/struct/E4997-BAY-2927088-Sevabertinib-chemical-structure.png |